195 related articles for article (PubMed ID: 34381018)
21. Disulfiram: an old therapeutic with new applications.
Barth KS; Malcolm RJ
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):5-12. PubMed ID: 20201810
[TBL] [Abstract][Full Text] [Related]
22. A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer.
Kim JY; Banerjee T; Vinckevicius A; Luo Q; Parker JB; Baker MR; Radhakrishnan I; Wei JJ; Barish GD; Chakravarti D
Mol Cell; 2014 May; 54(4):613-25. PubMed ID: 24793694
[TBL] [Abstract][Full Text] [Related]
23. MLL translocations, histone modifications and leukaemia stem-cell development.
Krivtsov AV; Armstrong SA
Nat Rev Cancer; 2007 Nov; 7(11):823-33. PubMed ID: 17957188
[TBL] [Abstract][Full Text] [Related]
24. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
[TBL] [Abstract][Full Text] [Related]
26. H3K27M in Gliomas Causes a One-Step Decrease in H3K27 Methylation and Reduced Spreading within the Constraints of H3K36 Methylation.
Harutyunyan AS; Chen H; Lu T; Horth C; Nikbakht H; Krug B; Russo C; Bareke E; Marchione DM; Coradin M; Garcia BA; Jabado N; Majewski J
Cell Rep; 2020 Nov; 33(7):108390. PubMed ID: 33207202
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial Lon is over-expressed in high-grade gliomas, and mediates hypoxic adaptation: potential role of Lon as a therapeutic target in glioma.
Di K; Lomeli N; Wood SD; Vanderwal CD; Bota DA
Oncotarget; 2016 Nov; 7(47):77457-77467. PubMed ID: 27764809
[TBL] [Abstract][Full Text] [Related]
28. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
29. HGF-MET signals via the MLL-ETS2 complex in hepatocellular carcinoma.
Takeda S; Liu H; Sasagawa S; Dong Y; Trainor PA; Cheng EH; Hsieh JJ
J Clin Invest; 2013 Jul; 123(7):3154-65. PubMed ID: 23934123
[TBL] [Abstract][Full Text] [Related]
30. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma.
Hashizume R; Andor N; Ihara Y; Lerner R; Gan H; Chen X; Fang D; Huang X; Tom MW; Ngo V; Solomon D; Mueller S; Paris PL; Zhang Z; Petritsch C; Gupta N; Waldman TA; James CD
Nat Med; 2014 Dec; 20(12):1394-6. PubMed ID: 25401693
[TBL] [Abstract][Full Text] [Related]
31. RIZ1: a potential tumor suppressor in glioma.
Zhang C; Zhu Q; He H; Jiang L; Qiang Q; Hu L; Hu G; Jiang Y; Ding X; Lu Y
BMC Cancer; 2015 Dec; 15():990. PubMed ID: 26690953
[TBL] [Abstract][Full Text] [Related]
32. MLL-AF4 Spreading Identifies Binding Sites that Are Distinct from Super-Enhancers and that Govern Sensitivity to DOT1L Inhibition in Leukemia.
Kerry J; Godfrey L; Repapi E; Tapia M; Blackledge NP; Ma H; Ballabio E; O'Byrne S; Ponthan F; Heidenreich O; Roy A; Roberts I; Konopleva M; Klose RJ; Geng H; Milne TA
Cell Rep; 2017 Jan; 18(2):482-495. PubMed ID: 28076791
[TBL] [Abstract][Full Text] [Related]
33. Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia.
Röhrs S; Dirks WG; Meyer C; Marschalek R; Scherr M; Slany R; Wallace A; Drexler HG; Quentmeier H
Mol Cancer; 2009 Oct; 8():86. PubMed ID: 19835597
[TBL] [Abstract][Full Text] [Related]
34. Proteolytically cleaved MLL subunits are susceptible to distinct degradation pathways.
Yokoyama A; Ficara F; Murphy MJ; Meisel C; Naresh A; Kitabayashi I; Cleary ML
J Cell Sci; 2011 Jul; 124(Pt 13):2208-19. PubMed ID: 21670200
[TBL] [Abstract][Full Text] [Related]
35. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia.
Wang E; Kawaoka S; Yu M; Shi J; Ni T; Yang W; Zhu J; Roeder RG; Vakoc CR
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3901-6. PubMed ID: 23412334
[TBL] [Abstract][Full Text] [Related]
36. SET/MLL family proteins in hematopoiesis and leukemia.
Yang W; Ernst P
Int J Hematol; 2017 Jan; 105(1):7-16. PubMed ID: 27796741
[TBL] [Abstract][Full Text] [Related]
37. Insights on the regulation of the MLL/SET1 family histone methyltransferases.
Sha L; Ayoub A; Cho US; Dou Y
Biochim Biophys Acta Gene Regul Mech; 2020 Jul; 1863(7):194561. PubMed ID: 32304759
[TBL] [Abstract][Full Text] [Related]
38. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket.
Song JJ; Kingston RE
J Biol Chem; 2008 Dec; 283(50):35258-64. PubMed ID: 18840606
[TBL] [Abstract][Full Text] [Related]
39. Does disulfiram have a role in alcoholism treatment today? Not to forget about disulfiram's psychological effects.
Ehrenreich H; Krampe H
Addiction; 2004 Jan; 99(1):26-7; author reply 27-8. PubMed ID: 14678057
[No Abstract] [Full Text] [Related]
40. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations.
Huang G; Zhao X; Wang L; Elf S; Xu H; Zhao X; Sashida G; Zhang Y; Liu Y; Lee J; Menendez S; Yang Y; Yan X; Zhang P; Tenen DG; Osato M; Hsieh JJ; Nimer SD
Blood; 2011 Dec; 118(25):6544-52. PubMed ID: 22012064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
